This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Cardiac troponin assay considerations

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Due to assay difficulties there were early concerns of the specificity of cardiac Troponin T in patients with renal failure, and also concerns that there was cross-reactivity with injured skeletal muscle. These problems do not occur with second and third generation assays for cardiac toponin T.

There are also multiple assays available for cardiac troponin I - which require standardisation. Assays for troponin I may also have problems due to interference by fibrin, heparin, heterophile antibodies and human anti-mouse antibodies. The latter may be a problem in those that either make antibodies or receive therapy with extrinsic antibodies.

For most clinical tests, the 97.5 percentile is used as a cut off for normality, but an editorial in Circulation (Sept 2000) suggested that for cardiac troponin T, cardiac troponin I and CK-MB the 99th percentile should be regarded as the upper limit.

Reference:

  • Jaffe A.S. et al. Editorial. It's Time for a Change to a Troponin Standard. Circulation. Sept 2000;102(11):1216.
  • Lindahl B. et al. Markers of myocardial damage and inflammation inrelation to long-term mortality in unstable coronary artery disease. NEJM 2000;343(16):1139-1147

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.